<DOC>
	<DOCNO>NCT02533362</DOCNO>
	<brief_summary>A 6 month safety , tolerability , efficacy pharmacokinetic study ANF-Rho treat patient chronic neutropenia .</brief_summary>
	<brief_title>ANF-Rho Treatment Chronic Neutropenia</brief_title>
	<detailed_description>Chronic neutropenia patient eligible participation screen enrolled receive open-label ANF-Rho period 6 month . Study participation separate 2 period , Induction ( 8 week ) Maintenance ( 16 week ) . Blood sample measure neutrophil level biochemistry labs drawn throughout study monitor efficacy response patient safety . Pharmacokinetic sample collect period questionnaire complete patient investigator bone pain , quality life ( QOL ) injection site reaction .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>1 . Patients 1 year age old 2 . Patients establish chronic neutropenia define Median Absolute Neutrophil Count ( ANC ) &lt; 0.5 x 109/L ( without demonstrate genetic lesion ) indication treatment , include : Independent hematological parameter , patient : ShwachmanDiamond syndrome ( SDS ) , Barth 's syndrome inherit disease associate neutropenia ( exclude Glycogen Storage Disease 1b ) 3 . Patients granulocytecolony stimulating factor ( GCSF ) &amp; PEGGCSF treatment still eligible participate washout period 7 day , stop drug 4 . Signed date informed write consent/assent patient/parent 5 . Women childbearing potential negative serum pregnancy test use reliable method contraception study period . Male study participant also agree use contraception study period . 1 . Evidence chromosomal abnormality , myelodysplasia , hematologic malignancy , aplastic anemia , systemic lupus erythematosus , rheumatoid arthritis ( Felty 's syndrome ) neutropenia druginduced 2 . Progressive malignant disease malignancy history 3 . Presence macrophage activation syndrome diagnosis neutropenia 4 . Clinical Significant Abnormal Renal , Cardiac , Hepatic Blood Coagulation disease . 5 . Chronic infection hepatitis B virus ( HBV ) , hepatitis C Virus ( HCV ) Human immunodeficiency virus ( HIV ) history tuberculosis 6 . Association anemia , thrombocytopenia ( low blood platelet ) diagnosis neutropenia . 7 . Drug abuse , substance abuse , alcohol abuse 8 . Use investigational drug time enrollment , within 5 halflives prior enrollment , whichever longer 9 . Patients unwilling and/or capable ensure compliance provision study protocol 10 . Women pregnant breastfeed 11 . Women childbearing potential use approve method birth control . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , post ovulation method ) acceptable 12 . Patients know DNA lossoffunction mutation GCSFR RUNX1 gene</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>